Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort

Digital vasculopathy in systemic sclerosis (SSc) consists of a spectrum of Raynaud's phenomenon (RP), digital ulcers (DUs), critical digital ischaemia and escalation to gangrene. The complications of severe digital vasculopathy often require hospital-based management with intravenous therapies and surgery.¹⁻³ Although gangrene is not infrequent in the clinic, data on the prevalence and

implications of gangrene in patients with SSc are scarce.^{3–7} The DU Outcomes (DUO) Registry is a European, prospective, multi-centre, observational cohort of patients with SSc and past and/or current DUs at enrolment.^{8–10} The aims of the current study were (i) to describe the characteristics of an SSc-DU population according to the presence/history of gangrene and (ii) to identify the risk factors for the development of incident gangrene.

All patients in the participating centres with SSc and a history or presence of DUs are eligible for inclusion in the DUO Registry, irrespective of their treatment regimen. At enrolment, data were collected on demographic and clinical variables. Patients were categorised into three groups according to their past history of gangrene and current gangrene status at enrolment: 'never gangrene': no past and no current gangrene; 'ever gangrene': past and/or current gangrene; and 'current gangrene': gangrene reported at enrolment, irrespective of gangrene history (a subset of the 'ever gangrene' group).

Categorical variables were analysed using descriptive statistics. Potential risk factors for the development of incident gangrene in patients with ≥ 1 follow-up visit and no current gangrene at enrolment were analysed using univariable logistic regression (ULR) conducted on demographics, clinical variables and auto-antibody measurements collected at enrolment. Multivariable logistic regression (MLR) using forward selection was conducted on patients with complete covariate information using those variables with a p value < 0.15 and sample size > 3000 from the ULR models, considering interdependency among similar factors.

Among the 4944 patients enrolled in the DUO Registry from April 2008 to November 2014, 4642 had information recorded on their gangrene status: 81.6% ($n=3787$) were categorised as 'never gangrene', 18.4% ($n=855$) as 'ever gangrene' and 5.6% ($n=258$) as 'current gangrene'. The three groups were generally similar regarding demographics and SSc characteristics, although

Table 1 Enrolment characteristics and patient demographics according to gangrene status*

	Never [†] gangrene ($n=3787$)	Ever [†] gangrene ($n=855$)	Current gangrene ($n=258$) [§]
Gender			
Female, %	82.1	77.7	77.5
Age at enrolment			
Mean (95% CI), years	54.4 (53.9 to 54.8)	54.8 (53.9 to 55.8)	52.8 (50.9 to 54.7)
Smoking status			
n	3386	757	233
Current, %	14.4	17.6	24.0
Former, %	23.3	25.6	17.6
Never, %	62.3	56.8	58.4
Pack-years of smoking			
n	868	206	73
Mean (95% CI)	37.8 (31.3 to 44.3)	37.9 (27.5 to 48.4)	44.9 (24.9 to 64.9)
Age at first RP			
n	3409	752	229
Mean (95% CI), years	41.3 (40.8 to 41.8)	40.7 (39.6 to 41.8)	41.2 (39.0 to 43.3)
Age at first DU			
n	3000	700	218
Mean (95% CI), years	47.6 (47.1 to 48.2)	47.1 (45.9 to 48.2)	48.3 (46.1 to 50.5)
SSc cutaneous subset			
n	3774	850	256
Diffuse SSc, %	37.7	32.0	33.6
Limited SSc, %	52.3	58.2	54.3
Overlap, %	6.5	6.0	7.8
Other, %	3.6	3.8	4.3
Organ manifestations			
n	3787	855	258
GI tract, %	54.0	56.8	46.5
Lung fibrosis, %	40.4	40.1	38.0
PAH, %	12.1	15.2	13.2
Heart, %	9.9	10.9	12.4
Kidney, %	4.1	6.0	5.8
Time from first RP to enrolment visit			
n	3409	752	229
Mean (95% CI), years	13.1 (12.8 to 13.5)	14.4 (13.6 to 15.3)	11.9 (10.4 to 13.5)
Time from first DU to enrolment visit			
n	3000	700	218
Mean (95% CI), years	5.9 (5.7 to 6.2)	7.4 (6.8 to 8.0)	4.6 (3.8 to 5.5)

Continued

Table 1 Continued

	Never [†] gangrene (n=3787)	Ever [‡] gangrene (n=855)	Current gangrene (n=258) [§]
Antibodies, n ¹ /n ² (%)			
ACA	1184/2942 (40.2)	303/668 (45.4)	88/216 (40.7)
ANA	3307/3511 (94.2)	750/785 (95.5)	226/238 (95.0)
Anti-Scl 70	1397/3145 (44.4)	282/690 (40.9)	87/218 (39.9)
Anti-U1 RNP	170/2158 (7.9)	52/470 (11.1)	17/151 (11.3)
Anti-U3 RNP	59/1534 (3.8)	19/300 (6.3)	4/104 (3.8)
RNA polymerase III	127/1584 (8.0)	25/323 (7.7)	6/103 (5.8)
Employed/self-employed, n (%)	983/2674 (36.8)	167/564 (29.6)	75/207 (36.2)
History of complications/interventions, % (95% CI) [¶]			
Critical digital ischaemia	30.1 (28.5 to 31.8)	82.2 (78.6 to 85.4)	69.4 (61.6 to 76.4)
Gangrene	–	91.7 (89.7 to 93.5)	71.9 (65.9 to 77.4)
Autoamputation	3.1 (2.6 to 3.7)	24.1 (21.2 to 27.2)	15.9 (11.6 to 21.1)
Soft-tissue infection requiring systemic antibiotics	23.9 (22.5 to 25.3)	53.5 (49.9 to 57.0)	44.5 (38.1 to 51.1)
Osteomyelitis	1.3 (0.9 to 1.7)	11.9 (9.7 to 14.3)	7.4 (4.4 to 11.4)
Hospitalisations for DUs	32.7 (31.2 to 34.2)	70.1 (66.9 to 73.2)	58.9 (52.5 to 65.2)
Upper limb sympathectomy	2.2 (1.8 to 2.7)	8.8 (6.9 to 10.9)	7.2 (4.2 to 11.2)
Digital sympathectomy	1.4 (1.0 to 1.8)	4.8 (3.4 to 6.5)	3.4 (1.5 to 6.6)
Arterial reconstruction	0.7 (0.5 to 1.0)	2.1 (1.3 to 3.4)	4.3 (2.1 to 7.7)
Arthrodesis	1.4 (1.0 to 1.9)	5.7 (4.1 to 7.6)	2.0 (0.5 to 4.9)
Debridement	7.5 (6.6 to 8.4)	25.7 (22.5 to 29.1)	21.0 (15.6 to 27.2)
Surgical amputation	2.4 (1.9 to 3.0)	34.0 (30.5 to 37.5)	18.9 (13.8 to 24.8)
Use of parenteral prostanoids	51.6 (49.9 to 53.2)	74.4 (71.2 to 77.4)	74.4 (68.3 to 79.8)
Prior DUs, n ¹ /n ² (%)	3759/3787 (99.3)	852/855 (99.6)	255/258 (98.8)
Ongoing medications, %			
n	3787	855	258
Analgesics and anti-inflammatories	52.4	60.6	65.1
Immunosuppressants	33.5	28.2	29.5
Systemic antibiotics	13.3	19.6	36.0
ERAs	39.9	52.0	50.4
CCBs	46.0	52.5	53.1
Prostacyclins	35.0	36.5	51.9
PDE-5i	5.9	7.6	5.8
Topical DU treatments	19.1	24.4	36.8
Other medications	64.8	74.2	67.1
ERA+PDE-5i	2.2	3.3	2.7
ERA+prostacyclin	14.3	18.5	24.4
PDE-5i+prostacyclin	1.7	2.8	3.1
ERA+PDE-5i+prostacyclin	0.8	1.5	1.6
ERA only**	24.1	31.8	24.8

*Only patients who provided information on gangrene status (n=4642/4944) were categorised.

[†]Patients with no past and no current gangrene.

[‡]Patients with past and/or current gangrene.

[§]Patients with current gangrene at enrolment. The current gangrene group is a subset of the 'ever gangrene' group.

[¶]Data include only patients who provided information on the given item.

**Out of ERA, PDE-5i and prostacyclins, only ERA is ticked.

ACA, anticentromere antibody; ANA, antinuclear antibody; CCB, calcium channel blocker; DU, digital ulcer; ERA, endothelin receptor antagonist; GI, gastrointestinal; n¹/n², n patients tested positive/n patients who had the test done; PAH, pulmonary arterial hypertension; PDE-5i, phosphodiesterase-type 5 inhibitor; RNP, ribonucleic protein; RP, Raynaud's phenomenon; SSc, systemic sclerosis.

more current smokers at enrolment were in the 'ever gangrene' and 'current gangrene' groups than in the 'never gangrene' group, and the 'current gangrene' group had the shortest time between first RP and enrolment (table 1). The proportion of patients with a history of DU-associated complications, interventions and hospitalisations was greater in the 'ever gangrene' group compared with the 'never gangrene' group.

Overall, 3809 patients were eligible for inclusion in the ULR analysis; the final number of patients included in each ULR

model varied depending on missing data (table 2A). On MLR analysis, being a current/former smoker, having ≥ 3 finger DUs, previous gangrene and previous upper limb sympathectomy were independent risk factors at enrolment for development of incident gangrene (table 2B).

This analysis was the largest to date describing an SSc-DU population according to the presence/history of gangrene at enrolment and risk factors for incident gangrene during follow-up. It has demonstrated that, in current practice, gangrene

Table 2 Risk factors associated with the development of incident gangrene during the observation period

Risk factor	Incident gangrene n/N (%)	No incident gangrene, n/N (%)	OR (95% CI)	p Value*
(A) ULR (N=3809) [†]	N=243	N=3566		
Female gender	189/243 (77.8)	2938/3566 (82.4)	0.73 (0.53 to 1.01)	0.055
Smoking status				
Current	45/205 (22.0)	438/3102 (14.1)	1.91 (1.32 to 2.76)	<0.001
Former	58/205 (28.3)	728/3102 (23.5)	1.46 (1.04 to 2.04)	0.028
Number of finger DUs at enrolment				
1–2	89/236 (37.7)	1315/3546 (37.1)	1.27 (0.93 to 1.72)	0.132
3+	58/236 (24.6)	666/3546 (18.8)	1.54 (1.09 to 2.17)	0.015
Anti-Scl 70	103/196 (52.6)	1279/2872 (44.5)	1.39 (1.04 to 1.87)	0.027
Previous gangrene	96/229 (41.9)	404/3378 (12.0)	4.75 (3.57 to 6.34)	<0.0001
Previous autoamputation	32/231 (13.9)	188/3386 (5.6)	2.69 (1.78 to 4.04)	<0.0001
Previous soft-tissue infection requiring systemic antibiotics	94/222 (42.3)	933/3253 (28.7)	1.76 (1.33 to 2.32)	<0.0001
Previous osteomyelitis	19/232 (8.2)	84/3367 (2.5)	3.24 (1.19 to 5.47)	<0.0001
Ongoing autoamputation	6/242 (2.5)	46/3552 (1.3)	2.32 (0.97 to 5.57)	0.059
Ongoing osteomyelitis	4/243 (1.6)	24/3558 (0.7)	2.36 (0.80 to 6.99)	0.121
Previous hospitalisation(s) for DUs (at least 1 day)	144/231 (62.3)	1290/3385 (38.1)	2.49 (1.89 to 3.29)	<0.0001
Previous upper limb sympathectomy	20/228 (8.8)	100/3345 (3.0)	3.24 (1.94 to 5.40)	<0.0001
Previous digital sympathectomy	11/228 (4.8)	58/3341 (1.7)	2.70 (1.38 to 5.31)	0.004
Previous arterial reconstruction	5/227 (2.2)	21/3336 (0.6)	3.43 (1.25 to 9.44)	0.017
Not employed/self-employed	205/243 (84.4)	2687/3566 (75.4)	1.78 (1.22 to 2.61)	0.003
(B) MLR [‡] (N=2479)	N=157	N=2322		
Observation time, mean (SD), weeks	174.7 (78.7)	126.2 (78.9)	1.03 (1.02 to 1.04)	<0.0001
Smoking status				
Current	27/157 (17.2)	311/2322 (13.4)	1.72 (1.07 to 2.77)	0.025
Former	47/157 (29.9)	509/2322 (21.9)	1.69 (1.14 to 2.51)	0.009
Number of finger DUs at enrolment				
1–2	60/157 (38.2)	951/2322 (41.0)	1.35 (0.90 to 2.03)	0.144
3+	46/157 (29.3)	491/2322 (21.1)	1.69 (1.09 to 2.62)	0.020
Anti-Scl 70	79/157 (50.3)	1031/2322 (44.4)	1.39 (0.99 to 1.96)	0.058
Previous gangrene	63/157 (40.1)	244/2322 (10.5)	4.67 (3.24 to 6.73)	<0.0001
Previous upper limb sympathectomy	15/157 (9.6)	67/2322 (2.9)	2.21 (1.15 to 4.27)	0.018

*Wald χ^2 test.[†]For the ULR analysis, observation time was a fixed covariate in the model. Data are shown for variables having p<0.15 and n>3000 for the patients for whom information is available).[‡]For the MLR analysis, observation time was forced into the model as a fixed covariate and not included by the forward selection procedure; variables were selected with a selection criterion of p=0.15. Data are shown for the subset of patients making up the final models (n=2479) to allow comparison with the full cohort.

ACA, anticentromere antibody; ANA, antinuclear antibody; DU, digital ulcer; MLR, multivariable logistic regression; PAH, pulmonary arterial hypertension; RNP, ribonucleic protein; ULR, univariable logistic regression.

is still a common event occurring in 18% of patients with SSc-DUs. Participating centres involved in the DUO Registry are specialist centres for the management of SSc-DUs; this may be selective for patients with more severe vascular disease, and therefore more prevalent gangrene. Multivariate analyses indicated that, in patients with no current gangrene, along with previous gangrene, being a current/former smoker, having ≥ 3 DUs and previous upper limb sympathectomy were independent risk factors at enrolment for developing incident gangrene. These results will help to risk-stratify patients with SSc-DUs and to evaluate preventive gangrene management strategies.

Yannick Allanore,¹ Christopher P Denton,² Thomas Krieg,³ Peter Cornelisse,⁴ Daniel Rosenberg,⁵ Barbara Schwierin,⁶ Marco Matucci-Cerinic,⁷ on behalf of the DUO Investigators

¹Department of Rheumatology A, Cochin Hospital, Paris Descartes University, Paris, France²Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, London, UK³Department of Dermatology, University of Cologne, Cologne, Germany⁴Department of Biostatistics, Actelion Pharmaceuticals, Allschwil, Switzerland⁵Department of Epidemiology and Observational Studies, GCS & E, Actelion Pharmaceuticals, Allschwil, Switzerland⁶Department of Global Clinical Development and Epidemiology, Actelion Pharmaceuticals, Allschwil, Switzerland⁷Division of Rheumatology AOU, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Correspondence to Professor Yannick Allanore, Service de Rhumatologie A, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, Paris 75014, France; yannick.allanore@inserm.fr

Acknowledgements Medical writing support was provided by Lynda McEvoy, PhD (ApotheCom, London, UK) and was funded by Actelion Pharmaceuticals.

Collaborators List of DUO investigators in online supplementary appendix.

Funding This DUO Registry is sponsored by Actelion Pharmaceuticals. The registry sponsor was involved in the registry design, and in the collection, analysis and interpretation of data.

Competing interests YA has had consultancy relationships and/or has received research funding in relation to the treatment of systemic sclerosis from Actelion Pharmaceuticals, Bayer, Biogen Idec, Bristol-Myers Squibb, Genentech/Roche, Inventiva, Medac, Pfizer, Sanofi/Genzyme, Servier and UCB. CPD has received consultant and speaker fees from Actelion Pharmaceuticals, GlaxoSmithKline, Bayer, Inventiva and Takeda, and has received grant support from Actelion Pharmaceuticals, CSL Behring, and Novartis. TK has received grant and speaker fees from Actelion Pharmaceuticals. PC is an employee of SDE Services, based 100% at Actelion Pharmaceuticals. DR and BS are employees of and own shares in Actelion Pharmaceuticals. MM-C has received grant/research support and/or speaker fees from Actelion Pharmaceuticals.

Ethics approval Ethical approval was obtained as required from the institutional ethics committees of the participating centres.

Provenance and peer review Not commissioned; externally peer reviewed.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2016-209481>).

OPEN ACCESS

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

CrossMark

To cite Allano Y, Denton CP, Krieg T, et al. *Ann Rheum Dis* 2016;**75**:1736–1740.

Received 3 March 2016

Revised 24 May 2016

Accepted 27 May 2016

Published Online First 27 June 2016

Ann Rheum Dis 2016;**75**:1736–1740. doi:10.1136/annrheumdis-2016-209481

REFERENCES

- 1 Sunderkötter C, Herrgott I, Brückner C, et al., DNSS Centers. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. *Br J Dermatol* 2009;160:835–43.
- 2 Denton CP, Korn JH. Digital ulceration and critical digital ischemia in scleroderma. *Scleroderma Care Res* 2003;1:12–16.
- 3 Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. *J Rheumatol* 2007;34:2423–30.
- 4 Elhai M, Avouac J, Walker UA, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. *Ann Rheum Dis* 2016;75:163–9.
- 5 Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. *Rheumatology (Oxford)* 2015;54:2015–24.
- 6 Amanzi L, Braschi F, Fiori G, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. *Rheumatology (Oxford)* 2010;49:1374–82.
- 7 Harrison BJ, Silman AJ, Hider SL, et al. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. *Arthritis Rheum* 2002;46:3312–6.
- 8 Guillevin L, Hunsche E, Denton CP, et al., DUO Registry Group. Functional impairment of systemic sclerosis patients with digital ulcerations: results from the DUO Registry. *Clin Exp Rheumatol* 2013;31(Suppl 76):71–80.
- 9 Denton CP, Krieg T, Guillevin L, et al., DUO Registry investigators. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. *Ann Rheum Dis* 2012;71: 718–21.
- 10 Matucci-Cerinic M, Krieg T, Guillevin L, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. *Ann Rheum Dis* Published Online First: 26 Nov 2015. doi:10.1136/annrheumdis-2015-208121